Kukjeon
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kukjeon supplies active pharmaceutical ingredients, the core chemical compounds that give finished medicines their therapeutic effect, to drug makers developing generic, improved, and novel drugs, and also develops and supplies high-purity specialty chemical materials used in semiconductor packaging and OLED display manufacturing.
Its pharmaceutical customers rely on it across the full development pipeline, from early-stage research through regulatory approval to commercial production. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct divisions: a long-established pharmaceutical ingredients business and a newer advanced materials business supplying additives and antistatic agents for high-bandwidth memory chips and OLED common-layer materials.
Summary is AI-generated and may contain errors · figures from DART filings
The company is in the process of changing its registered name from Kukjeon Pharmaceutical to Kukjeon, reflecting its strategic expansion beyond pharmaceutical ingredients into advanced industrial materials.
Kukjeon in five facts
What does Kukjeon do?
Kukjeon supplies active pharmaceutical ingredients, the core chemical compounds that give finished medicines their therapeutic effect, to drug makers developing generic, improved, and novel drugs, and also develops and supplies high-purity specialty chemical materials used in semiconductor packaging and OLED display manufacturing.
Where is Kukjeon listed and in which sector?
Kukjeon (Korean name: 국전) trades under KRX code 307750 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kukjeon?
Its market capitalisation was US$107.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kukjeon's latest annual revenue and operating profit?
For fiscal year 2025, Kukjeon reported revenue of US$98.9M, an operating loss of US$1.9M and a net loss of US$3.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 4.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 6
- [Amended] Half-year report (2026.06)Oct 2
- Report on large shareholdings (5% rule) (standard)Sep 18
- Report on large shareholdings (5% rule) (standard)Sep 3
- Early redemption of bonds with warrants
Kukjeon Co., Ltd. acquired before maturity US$4.82M in face value of its Series 3 domestic private-placement bonds with warrants on August 27, 2026, following a bondholder's exercise of early-redemption rights, leaving US$15.8M in face value outstanding.
Capital raise · Aug 27 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kukjeon reported consolidated results for FY2025: revenue of US$90.9M (−3.9% year on year), an operating loss of US$1.79M (from a profit a year earlier) and a net loss of US$3.35M (from a profit a year earlier).
Earnings · Feb 13